PRESS RELEASES

Archives

September 18, 2017 - Optinose Announces FDA approval of XHANCE™ (fluticasone propionate) nasal spray for the treatment of nasal polyps

May 9, 2017 - OptiNose Raises $37 Million in Series D Funding Led by Fidelity

February 9, 2017 - Michael F. Marino Joins OptiNose as Chief Legal Officer

January 31, 2017 - OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375

January 27, 2017 - OptiNose Appoints Keith Goldan as Chief Financial Officer

October 7, 2016 - Tom Gibbs Joins OptiNose™ as Chief Commercial Officer

September 19, 2016 - New Research Highlights the Burden of Illness Suffered by Chronic Rhinosinusitis Patients

September 16, 2016 - OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis (CRS) with and without Nasal Polyps

February 1, 2016 - OptiNose® Announces Pipeline Project to Evaluate Nose-to-Brain Application of Bi-Directional™ Breath Powered® Technology Selected for Norwegian Government Funding

January 28, 2016 - OptiNose Announces FDA Approval for ONZETRA™ Xsail™ (sumatriptan nasal powder), a New Treatment for Acute Migraine Using Bi-Directional™ Breath Powered® Technology